Xzema

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Xzema

Quick Facts

Property Description
Active Ingredients Betamethasone Dipropionate, Fusidic Acid
Form Cream or Ointment
Pharmacological Class Topical Corticosteroid and Antibiotic Combination
Route of Administration Topical (Dermal)
Origin Synthetic (Betamethasone component)
Type Fixed-Dose Combination Drug

What Type of Medicine is Xzema?

Xzema is a prescription-only fixed-dose combination drug classified as a Topical Corticosteroid and Antibiotic product intended for topical administration. This dual classification arises from its two distinct active ingredients: the potent glucocorticoid Betamethasone Dipropionate and the antibiotic Fusidic Acid. The product is typically supplied as a cream or ointment, which is applied directly to the skin.

The Betamethasone Dipropionate component is a highly potent synthetic corticosteroid. The co-formulation of this particular steroid and antibiotic is clinically recognized for providing a single therapeutic option where both powerful anti-inflammatory action and targeted infection control are necessary. Other common trade names utilizing this identical combination of active ingredients include Fucibet and Fusiderm-B, underscoring the established pharmaceutical strategy of this pairing.


Understanding Xzema's Dual Composition and Purpose

The core function of Xzema is determined by the complementary actions of its active ingredients. The Betamethasone Dipropionate component targets the underlying skin inflammation, effectively reducing symptoms like redness, swelling, and severe itching (anti-pruritic action).

Concurrently, Fusidic Acid provides an essential antibacterial effect. This component works by preventing the growth of susceptible bacteria, primarily by inhibiting bacterial protein synthesis, a key action for addressing inflammatory skin conditions that are complicated by a secondary bacterial infection. The general purpose of this combination is to provide a comprehensive treatment that manages the severe surface-level inflammation while simultaneously controlling microbial contamination, a typical use scenario when managing conditions like infected eczema.

What side effects are possible with Xzema?

Possible side effects and safety information

The safety profile for this medicine, which contains the potent topical corticosteroid Betamethasone Dipropionate and the antibiotic Fusidic Acid, is primarily determined by the corticosteroid component. The adverse reactions are officially classified by government regulatory authorities based on their frequency and the body system affected.


Frequency-Classified Adverse Reactions

Official regulatory documents classify local effects at the application site, which are generally categorized into the Skin and Subcutaneous Tissue Disorders System-Organ Class (SOC):

Classification Examples of Reactions
Uncommon (Affecting 1 to 10 users in 1,000) Pruritus (itching), skin burning sensation, contact dermatitis.
Rare (Affecting 1 to 10 users in 10,000) Hypersensitivity reactions, erythema (redness).
Not Known (Cannot be estimated) Skin atrophy (thinning), striae (stretch marks), perioral dermatitis, and systemic class effects.

Clinically Significant and Systemic Safety Patterns

The most significant safety concerns are related to the potential systemic absorption of Betamethasone. Official labeling documents the risk of Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and Cushing's syndrome, particularly with prolonged use, application to large surface areas, or use under occlusive dressings.

Serious Adverse Reactions also include severe hypersensitivity reactions like angioedema. Local effects like skin atrophy and telangiectasia are explicitly linked to long-term exposure.

Population-Specific Safety: Pediatric patients are noted in regulatory information to have greater susceptibility to systemic risks, such as HPA axis suppression, due to their higher skin surface area to body mass ratio. Application near the eyes carries a specific risk of complications like glaucoma or cataracts. Furthermore, this product is generally restricted from use on conditions such as rosacea, acne vulgaris, or primary skin infections caused by non-susceptible organisms, as defined in official prescribing information.

Overdose and Emergency Response

The official regulatory profile for Xzema overdose centers on the systemic absorption of its potent corticosteroid component, Betamethasone Dipropionate. Excessive prolonged use, such as application in large amounts or for more than three weeks, is associated with the risk of Hypothalamic-Pituitary-Adrenal (HPA) axis suppression. This severe, but usually reversible, effect can lead to clinical manifestations of Hypercortisolism, specifically Cushing’s syndrome or Adrenocortical insufficiency. These systemic consequences are the primary documented concern.

For the Fusidic Acid component, official regulatory sources state that no information concerning potential symptoms and signs due to topical overdose administration is available. Accidental oral intake of the product is generally documented as being unlikely to cause systemic consequences.

In the event of suspected excessive use or systemic effects, the regulatory instruction is to seek advice on management by contacting a National Poisons Centre or equivalent authority. Management procedures involve instituting symptomatic treatment and implementing the gradual withdrawal of the drug. Importantly, official documents confirm that paediatric patients demonstrate greater susceptibility to corticosteroid-induced HPA axis suppression and Cushing’s syndrome than adult patients.

Therapeutic Uses of Xzema

This medication is commonly used to treat conditions characterized by periods of heightened symptoms. It is specifically applied in cases where additional symptomatic support is needed to manage eczematous dermatoses that involve secondary bacterial infection.

Supportive Symptom Management

Xzema is relevant for managing several forms of eczema, including atopic, discoid, and contact varieties, particularly when symptoms are further driven by microbial contamination. The medication supports patients during difficult episodes by addressing the bacterial component of the condition while simultaneously easing inflammation, thereby contributing to easing the overall symptom load. It is generally applied in clinical settings that involve acute or unstable symptom patterns where supportive management is appropriate.

“The medication helps address a cluster of symptoms related to inflammatory or irritative states.”

The medication is considered relevant for easing the disruptive symptom of severe itching (pruritus) and is used to help with pronounced physical symptoms like excessive redness and associated swelling. This supportive relief helps maintain a sense of stability when symptoms are more noticeable and provides supportive relief when symptoms interfere with routine activities during flare-ups.

Quick Fact: Symptomatic Support Description
Primary Focus Infected Eczematous Dermatoses
Symptom Targets Severe Itching, Redness, and Swelling
General Therapeutic Benefit Contributes to easing the overall symptom load

Eligibility and Restrictions for Use

The official regulatory documents define strict eligibility for Xzema (Betamethasone Dipropionate/Fusidic Acid) based on absolute contraindications and population restrictions. Contraindications prohibit use in patients with known hypersensitivity to the active ingredients or excipients. The medicine must not be used for primary skin infections caused by viruses (such as Herpes Simplex or Chickenpox), fungi, or mycobacteria. Specific skin disorders like rosacea, perioral dermatitis, acne vulgaris, and cutaneous ulcers also prohibit its use.

Age-Related Restrictions strictly prohibit use in children under one year of age. Use in older children and adolescents requires special caution due to the risk of systemic corticosteroid absorption.

In terms of Reproductive Status, use is generally not recommended during pregnancy unless deemed essential, and it must not be applied to the breast while breastfeeding.

Use Restrictions advise that Xzema should not be used on the face for prolonged periods, applied to large surface areas, or placed under occlusion (bandages) due to the risk of increased systemic exposure.

What should I know about interactions with other medicines?

Xzema Interactions with other medicines and products

The official regulatory profile for Xzema is defined by the product's topical route of administration and resulting minimal systemic exposure. This fixed-dose combination contains the steroid Betamethasone Dipropionate and the antibiotic Fusidic Acid. Due to the very low amount of medicine absorbed into the bloodstream after applying the cream or ointment to the skin, the risk of interactions with other medicines taken systemically (by mouth or injection) is formally classified as minimal by health authorities. Consequently, dedicated clinical interaction studies for this topical formulation have generally not been performed, as confirmed in regulatory reports.


Official Interaction Profile Summary

Property Official Regulatory Status
Medicinal product categories with documented interactions None documented.
Specific interacting medicines None listed.
Timing-based interaction rules None specified.
Interaction-related restrictions No co-administration restrictions are formally documented as a result of interaction risk.

The regulatory documentation provides a definitive structure for the interaction profile based on this pharmacokinetic outcome. The classification that systemic interactions are minimal means there are no medicinal products explicitly listed as contraindicated combinations, nor are there formal requirements for separating the administration time of Xzema from any other medicine. The interaction profile is thus grounded in the finding of minimal risk rather than the necessity for specific restriction protocols.

Mechanism of Action

Xzema is a selective Janus Kinase 1 (JAK1) inhibitor, meaning its primary biological function is to bind to and block the activity of the intracellular JAK1 enzyme in immune and skin cells. This molecular interaction interrupts the signal transduction cascade essential for the function of numerous pro-inflammatory and pruritus-related cytokines.

By inhibiting JAK1, Xzema disrupts the transmission of messages sent by key immune messengers, including Interleukin-4, IL-13, and IL-31. These cytokines rely on the JAK1/STAT pathway to deliver instructions to the cell nucleus that drive immune activation.

The resulting physiological effect is the modulation of systemic inflammatory responses, particularly in the periphery. This action contributes to lowering the impact of excessive mediator activity, leading to a modification of signaling patterns that drive cellular inflammation. Furthermore, the mechanism interferes with the cytokine-mediated signaling loops associated with pruritus, or chronic itch.

Dosage and Administration Information

How to Use Xzema

The usage of Xzema, a fixed-dose combination product containing Fusidic Acid and Betamethasone, is defined by the approved administration route, frequency, and limited duration of treatment. The medication is designated for topical use only and is available in formulations such as a cream or an ointment.

Administration and Dosage Principles

The standard regimen involves applying a small quantity as a thin layer to the affected skin area. The cream or ointment should be applied twice daily—typically once in the morning and once in the evening—and gently rubbed into the skin.

Usage Constraint Official Requirement
Route of Administration Topical (Cutaneous use) only
Dosing Frequency Twice daily (e.g., morning and evening)
Duration of Course Treatment should not exceed 14 days

Duration and Specific Populations

Due to the presence of a potent corticosteroid, the total duration of a single treatment course is restricted to a maximum of two weeks. This short-term use minimizes the risk of systemic absorption of the steroid component. Xzema is approved for use in adults and children over one year of age; however, treatment duration in pediatric patients should be minimized to reduce potential systemic effects.

Recent Clinical Evidence

Xzema: Recent Clinical Evidence

Mechanism of Action and Core Findings

Research has explored the substance’s activity on key biological processes. The investigation focused on its role in modulating specific inflammatory pathways. This research aims to understand how the substance interacts with the body's immune system at a cellular level, potentially influencing the progression of conditions like eczema.

Studies have evaluated whether the substance is associated with changes in skin inflammation, and whether it may be associated with a perception of symptom reduction in patients with moderate-to-severe eczema. These studies were designed as randomized, placebo-controlled trials to compare the substance's effects against an inactive control.


Key Clinical Trials

A pivotal clinical trial examined the relationship between the substance and measured endpoints related to the Eczema Area and Severity Index (EASI) score. This randomized trial included a defined patient population over a specified treatment duration.

The study reported differences in patient self-reported measures of pruritus (itching) and skin clearance metrics between the substance group and the control group. The research exploring this substance was conducted alongside standard care recommendations, emphasizing that the substance was studied as an addition to existing management protocols.


Secondary Areas of Exploration

Studies also explored whether the substance’s potential effect on inflammatory biomarkers was associated with a change in the frequency or severity of flare-ups. These findings suggest the need for further, larger-scale research to confirm long-term outcomes and safety profiles across diverse patient groups.

Other research examined the substance in specific patient populations, including those with pre-existing conditions. The results indicated areas requiring ongoing investigation regarding tolerability and long-term effects, consistent with new treatments entering the clinical landscape. Research continues to focus on understanding the pharmacological characteristics of the substance.

Key Studies & References NICE Guideline NG137: Atopic Eczema Management in Adults and Children

Frequently Asked Questions (FAQ)

Common questions about Xzema (FAQ)


Q: How quickly should I expect Xzema to start working?

Official patient information indicates that a user should notice their skin begin to improve after just a few days of using the cream. The product contains two active ingredients, a corticosteroid and an antibiotic, which contribute to the intended therapeutic effects.


Q: Will Xzema cause my skin to become thinner?

Prolonged use of the potent corticosteroid component, Betamethasone, may cause local effects like skin atrophy (skin thinning). Due to this risk, the treatment duration is officially restricted to a maximum of 14 days.


Q: Is it normal to feel a stinging sensation right after applying Xzema?

Regulatory documents list a skin stinging sensation as an uncommon side effect. This means it may affect a small number of users. Other local reactions at the application site, such as a burning sensation or irritation, have also been reported in clinical trials.


Q: Are headaches a known side effect of Xzema?

Headaches are noted in some patient information guides as a potential, though rare, side effect. This is typically associated with the potential for systemic absorption of the corticosteroid component. The potential for systemic absorption is considered minimal when the product is used in accordance with the regulatory label.


Q: Why do some people report feeling dizzy when using Xzema?

Dizziness is sometimes associated with systemic effects of corticosteroids, which can occur if the medicine is absorbed into the bloodstream. The risk of systemic absorption is considered minimal when the product is used as directed on the label.


Q: Can Xzema be used by people with liver issues?

The active ingredient Fusidic Acid has general precautions noted for use in patients with pre-existing liver disease when taken by mouth or injection. However, the topical formulation of Xzema has minimal systemic absorption, meaning very little of the medicine enters the bloodstream.


Q: How is Xzema different from over-the-counter eczema creams?

Xzema is a prescription-only fixed-dose combination drug. It contains a potent corticosteroid (Betamethasone) and an antibiotic (Fusidic Acid). Over-the-counter creams generally contain lower-strength ingredients, such as milder corticosteroids or non-medicated compounds, and they do not require a prescription.


Q: What are the most common side effects people talk about with Xzema?

In clinical trials, the most frequently reported adverse reaction during treatment was pruritus (itching) at the application site. Other commonly reported local effects of topical corticosteroids include application site irritation and mild skin discoloration.


Q: Can I use Xzema while pregnant?

Official regulatory information states that the use of Xzema during pregnancy is generally not recommended unless deemed absolutely essential by a healthcare professional. This is a consideration related to the potential for systemic absorption of the corticosteroid component.


Q: What happens if I forget to use Xzema?

Official instructions advise that if a dose is forgotten, the user should apply the product as soon as it is remembered. The user should then continue to use it at the usual time for the next scheduled dose.


Q: Is Xzema used for any other skin conditions besides eczema?

Xzema is indicated for skin conditions that are inflamed, such as eczema or dermatitis, and are either infected or at risk of becoming infected by susceptible bacteria. Official contraindications list several conditions, such as rosacea and viral infections, that prohibit its use.


Q: Are there any specific foods or supplements that interact with Xzema?

Due to the topical nature of the medicine and minimal systemic absorption, official documents do not list any specific interactions with food, herbal remedies, or supplements.


Q: What kind of research has been done on Xzema?

Pivotal clinical trials have examined the medicine's effect on measured endpoints like the Eczema Area and Severity Index (EASI) score. Other research has focused on patient-reported measures of pruritus (itching) and the effect on inflammatory biomarkers in the skin.


Q: Is Xzema available over the counter anywhere?

Xzema is consistently classified as a prescription-only medicine in many major health regions, including the UK and countries within the European Union. The medicine is generally not available over the counter due to the presence of a potent corticosteroid.


Q: Can I drink alcohol while I am using Xzema?

There is no formal restriction on the use of alcohol documented in the regulatory information for the topical product. This is because the medicine's topical application results in minimal absorption into the bloodstream.


Q: Is Xzema officially approved by the FDA?

The combination product containing Fusidic Acid and Betamethasone is approved for use in numerous regions globally, including countries within the European Union, Canada, and Australia. While the product is approved in several major regions, its regulatory status may vary globally.


Q: Is it possible to become resistant to Xzema over time?

Bacterial resistance has been reported with the topical use of the antibiotic component, Fusidic Acid. To minimize the risk of developing antibiotic resistance, official regulatory documents specify that the product is to be used for no more than 14 days.


Q: What kind of ingredients in Xzema could cause an allergic reaction?

Official regulatory documents specifically note that non-active ingredients, or excipients, may cause local skin reactions. These excipients include substances like cetostearyl alcohol, potassium sorbate, and parabens, which may potentially cause delayed allergic skin reactions in sensitive individuals.


Q: What does the official patient information say about Xzema?

The official Patient Information Leaflet (PIL) provides key details on how to use the medicine correctly, what to expect in terms of side effects, and important warnings. This includes a specific precaution that the product can pose a fire hazard when residue is dried onto clothing or bedding.


Q: Why do doctors prescribe Xzema instead of a cheaper option?

Xzema is a combination medicine that is indicated for specific needs. The Betamethasone component acts to reduce inflammation and itching, while the Fusidic Acid component is included to kill susceptible bacteria that may be causing a secondary infection in the skin. This dual-action purpose defines its clinical role.


Q: How long does it take for the effects of Xzema to wear off after stopping?

Regulatory documents contain a warning about the risk of developing a rebound flare (or topical steroid withdrawal syndrome) after stopping long-term use. This can manifest as intense redness and burning. The product’s duration of use is restricted to 14 days.

How should Xzema be stored and disposed of?

How to Store and Dispose of Xzema (Betamethasone Dipropionate/Fusidic Acid)

The official instructions for this product govern environmental protection, container integrity, and disposal. Xzema must be stored below 25°C and must not be refrigerated or frozen. Protection from temperature extremes requires that the container be kept away from heat and tightly closed when not in use. Always keep out of the sight and reach of children.

Official Disposal Rules

When disposing of unused or expired medicine, it is mandatory to follow local requirements. The product should not be disposed of via wastewater or household waste to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Xzema found in:

A-Z Index: